3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
35
Carcinoma, Neuroendocrine
10
Carcinoid Tumor
10
Neoplasms
6
Adenoma, Islet Cell
6
Carcinoma, Renal Cell
5
Carcinoma, Islet Cell
5
Somatostatinoma
4
Pheochromocytoma
4
Insulinoma
4
Glucagonoma
4
Carcinoma, Medullary
4
Paraganglioma
3
Neoplasm Metastasis
3
Gastrinoma
3
Carcinoma
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Neuroectodermal Tumors, Primitive
2
Liver Neoplasms
2
Head and Neck Neoplasms
2
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Adenocarcinoma, Follicular
2
von Hippel-Lindau Disease
1
Zollinger-Ellison Syndrome
1
Tuberous Sclerosis
1
Interventions
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Octreotide
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Malignant Carcinoid Syndrome
×
Everolimus
×
Endocrine
×
Clear all
NCT00412061
2014-11-21
RADIANT-2
Novartis
Phase 3
Completed
429 enrolled
13 charts